JERUSALEM--(BUSINESS WIRE)--Jan. 25, 2018--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it
will issue a press release on its fourth quarter and full year 2017
financial results on Thursday, February 8, 2018 at 7:00 a.m. ET.
Following the release, Teva will conduct a conference call and live
webcast on the same day, at 8:00 a.m. ET.
In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): United States 1-866-869-2321;
Canada 1-866-766-8269 or International +44(0) 203 0095710; passcode:
5279244. For a list of other international toll-free numbers, click here.
A live webcast of the call will also be available on Teva's website at: www.ir.tevapharm.com.
Please log in at least 10 minutes prior to the conference call in order
to download the applicable audio software.
Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company's website. The replay can also
be accessed until March 8, 2018, 9:00 a.m. ET by calling United States
1-866-247-4222; Canada 1-866-878-9237 or International +44(0)
1452550000; passcode: 5279244.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by approximately 200 million
patients in 60 markets every day. Headquartered in Israel, Teva is the
world’s largest generic medicines producer, leveraging its portfolio of
more than 1,800 molecules to produce a wide range of generic products in
nearly every therapeutic area. In specialty medicines, Teva has the
world-leading innovative treatment for multiple sclerosis as well as
late-stage development programs for other disorders of the central
nervous system, including movement disorders, migraine, pain and
neurodegenerative conditions, as well as a broad portfolio of
respiratory products. Teva is leveraging its generics and specialty
capabilities in order to seek new ways of addressing unmet patient needs
by combining drug development with devices, services and technologies.
Teva's net revenues in 2016 were $21.9 billion. For more information,
visit www.tevapharm.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180125006039/en/
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
IR Contacts:
United States
Kevin
C. Mannix, 215-591-8912
or
Israel
Ran Meir,
972 (3) 926-7516
or
Tomer Amitai, 972 (3)
926-7656
or
PR Contacts:
Israel
Iris Beck Codner,
972 (3) 926-7208
or
United States
Kaelan Hollon,
202-412-7076